On June 24 and June 25, Axinn partners Aziz Burgy and Chad Landmon spoke at ACI's 10th Annual Summit on Biosimilars Conference in New York. Aziz participated in the, "Challenging Patents on Reference Drugs at the PTAB in the Age of Reform" panel and Chad participated in the, "Naming, Labeling and Marketing Biosimilars: Overcoming Inherent Barriers to Break into the U.S. Marketplace" panel.

This two-day event promoted the discussion of the future of biosimilars and formulated solutions to the complex regulatory and patent challenges ahead with industry leaders from both innovator and biosimilar companies.